Wickerham D Lawrence, O'Connell Michael J, Costantino Joseph P, Cronin Walter M, Paik Soonmyung, Geyer Charles E, Ganz Patricia A, Petrelli Nicholas, Mamounas Eleftherios P, Julian Thomas B, Wolmark Norman
NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Semin Oncol. 2008 Oct;35(5):522-9. doi: 10.1053/j.seminoncol.2008.07.005.
The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the monoclonal antibody trastuzumab in women with HER2-positive breast cancer are all the direct results of research that has been carried out over the past 50 years by the National Surgical Adjuvant Breast and Bowel Project (NSABP). This National Cancer Institute-supported clinical cooperative trials group based in Pittsburgh, PA, currently has 200 member institutions and 700 satellite centers located throughout the United States, Canada, Puerto Rico, and Ireland. The NSABP's mandate is to conduct large randomized phase III trials to evaluate therapies designed to improve the treatment and prevention of breast and colorectal cancer. Over the past half century, the NSABP has entered more than 150,000 patients and participants into clinical studies that have changed the treatment of colorectal cancer and have revolutionized the treatment and prevention of breast cancer.
根治性乳房切除术被单纯乳房切除术取代，随后又被肿块切除术加放疗所取代；辅助治疗用于改变乳腺癌和结直肠癌的自然病程；他莫昔芬用于预防乳腺癌；以及使用单克隆抗体曲妥珠单抗治疗HER2阳性乳腺癌患者所带来的生存率显著提高，这些都是美国国家乳腺与肠道外科辅助治疗项目（NSABP）在过去50年所开展研究的直接成果。这个由美国国立癌症研究所支持的临床合作试验小组位于宾夕法尼亚州匹兹堡，目前在美国、加拿大、波多黎各和爱尔兰拥有200个成员机构和700个卫星中心。NSABP的任务是开展大型随机III期试验，以评估旨在改善乳腺癌和结直肠癌治疗与预防的疗法。在过去的半个世纪里，NSABP已将超过150,000名患者和参与者纳入临床研究，这些研究改变了结直肠癌的治疗方式，并彻底革新了乳腺癌的治疗与预防方法。
